A New Chapter in Diabetes and Obesity Care Perhaps the most important lesson from the GLP-1 story is that medicine is beginning to think differently about chronic disease
While each medication has different dosing schedules, pen designs, and clinical indications, the fundamental injection technique is the same: a subcutaneous injection (under the skin) administered once per week
It is available as a standard benefit to Tier 3 IFMA members
And yes, weve seen the power of Semaglutide up close
Conservative escalation is particularly relevant for people who have tried Semaglutide or Tirzepatide before and experienced significant nausea
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
